

1st March, 2024

- | | |
|---|---|
| <p>(1) BSE Ltd
Listing Department
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai 400 001
Scrip Code: 500087</p> | <p>(2) National Stock Exchange of India Ltd
Listing Department
Exchange Plaza, 5th floor,
Plot no. C/1, G Block,
Bandra Kurla Complex,
Bandra (East), Mumbai - 400 051
Scrip Code: CIPLA EQ</p> |
| <p>(3) SOCIETE DE LA BOURSE DE LUXEMBOURG
Societe Anonyme
35A Boulevard Joseph II,
L-1840 Luxembourg</p> | |

Dear Sir / Madam,

Sub: Update on incorporation of a joint venture company in USA

In compliance with the provisions of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and in furtherance to our intimation dated 5th January, 2024 regarding the joint venture agreement entered between Cipla (EU) Limited, wholly owned subsidiary of the Company in UK, with Kemwell Biopharma UK Limited and MNI Ventures ("JV Partners"), we hereby notify that the JV Partners have received confirmation of incorporation of joint venture company "MKC Biotherapeutics Inc." from Secretary of State, Delaware, USA on 29th February, 2024. The effective date of incorporation is 27th February, 2024.

Kindly take the above information on records

Yours faithfully,
For Cipla Limited

Rajendra Chopra
Company Secretary

Prepared by: Muskan Jain